When researchers pooled data from six major clinical trials of semaglutide, the drug behind Ozempic and Wegovy, they found something that had been hoped for but never confirmed at this scale: adults aged 65 and older lost roughly the same proportion of body weight as younger participants, and their blood pressure, blood sugar, and inflammatory markers improved in lockstep. The analysis, led by Luca Busetto of the University of Padova and supported by Novo Nordisk, tracked outcomes over 68 weeks in participants receiving the weekly 2.4 mg dose. As of June 2026, it represents some of the most comprehensive evidence that semaglutide can safely and meaningfully benefit older adults, a population that has historically been underrepresented in obesity drug trials.
That matters because obesity among Americans over 65 is no longer a secondary concern. According to the CDC’s most recent prevalence data, more than 40% of adults aged 60 and older now meet the clinical threshold for obesity, carrying elevated risks of heart disease, type 2 diabetes, mobility loss, and early death. For decades, the standard advice for older adults was modest calorie reduction and gentle exercise. Semaglutide has changed the calculus.
What the trials actually showed
The foundation is STEP 1, a randomized, placebo-controlled trial published in The New England Journal of Medicine. In that study, adults with overweight or obesity who did not have diabetes received semaglutide 2.4 mg weekly and lost an average of about 15% of their body weight over 68 weeks, compared with roughly 2.4% in the placebo group. STEP 1 set the protocols, endpoint definitions, and adverse-event tracking that every subsequent trial in the program would follow.
Durability came from STEP 5, which extended follow-up to 104 weeks. That trial, published in Nature Medicine, confirmed that weight loss and improvements in blood pressure, waist circumference, and glycemic control persisted over two full years of continuous treatment. For older adults facing compounding metabolic risks, a drug that works for a few months is far less useful than one whose benefits hold over years.
The cardiovascular case rests on SELECT, a landmark trial also published in The New England Journal of Medicine. SELECT enrolled adults with established cardiovascular disease and overweight or obesity but without diabetes. Over a median follow-up of roughly 40 months, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared with placebo (hazard ratio 0.80). That result was not driven solely by weight loss; researchers pointed to reductions in systemic inflammation, improved lipid profiles, and better blood pressure control as likely contributing mechanisms. The mean age in SELECT skewed older than in the earlier STEP trials, making its findings especially relevant for adults in their 60s and 70s.
The Busetto pooled analysis drew from STEP 1, 3, 4, 5, 8, and 9 to isolate outcomes specifically in participants aged 65 and older. Across those trials, older adults achieved clinically meaningful reductions in body weight and waist circumference, along with improvements in fasting glucose, HbA1c, and blood pressure. Critically, the rate of serious adverse events in older participants did not spike disproportionately compared with younger cohorts.
A separate line of evidence comes from the STEP-HFpEF Programme, which tested semaglutide in patients with obesity-related heart failure with preserved ejection fraction. An age-stratified analysis found consistent improvements in heart failure symptoms and physical function across patients aged 65 to 74 and those 75 and older. Formal interaction testing showed no significant difference in treatment effect by age group, meaning the drug’s benefits did not fade as patients got older.
The gaps that still worry clinicians
No trial in the STEP program was designed exclusively for adults over 75. The pooled analyses and subgroup breakdowns are encouraging, but the number of participants in their late 70s and 80s within any single study is relatively small. That limits the ability to detect rare adverse events that disproportionately affect the oldest patients: falls triggered by rapid weight loss, dehydration from persistent nausea or diarrhea, or the worsening of frailty syndromes that can turn a modest setback into a hospitalization.
Gastrointestinal side effects remain the most common complaint across all semaglutide trials. Nausea, vomiting, diarrhea, and constipation typically appear during dose escalation and often ease over weeks. But the published data do not isolate how these side effects interact with polypharmacy, a near-universal reality for adults over 75, many of whom take five or more daily medications. Whether semaglutide-related appetite suppression or intermittent vomiting compounds nutritional deficiencies or interferes with absorption of other drugs is a question the current evidence cannot fully resolve.
Then there is sarcopenia, the progressive loss of muscle mass that accelerates with age. Any significant weight loss in an older adult carries a documented risk of stripping away lean tissue along with fat, potentially increasing fall risk and eroding the physical independence that defines quality of life. The STEP trials measured body weight and waist circumference but did not publish detailed body composition data (fat mass versus lean mass) for the over-65 subgroups. Clinicians are left to infer from broader aging research that some muscle loss is likely, and to recommend resistance training and higher protein intake as countermeasures, though no randomized trial has yet tested that combination alongside semaglutide in older adults.
Regulatory agencies have not issued age-specific dosing guidance for semaglutide. The FDA’s approved indications for chronic weight management (Wegovy) and cardiovascular risk reduction do not include separate recommendations for patients over 75. Physicians treating the oldest patients are extrapolating from trial populations whose participants were, on average, younger and likely healthier than the broader community of older adults living with multiple chronic conditions.
Cost and access add another layer of complexity. Semaglutide for weight management carries a list price exceeding $1,300 per month. While Medicare Part D coverage for anti-obesity medications has been a subject of ongoing legislative debate, many older adults on fixed incomes face significant out-of-pocket costs or outright coverage denials. A drug with strong clinical evidence is only useful if patients can actually obtain it.
What this means for older adults weighing treatment
The combined evidence from STEP 1, STEP 5, SELECT, the Busetto pooled analysis, and STEP-HFpEF builds a case that is unusually strong for any obesity treatment in older populations. Semaglutide reduces body weight by a clinically significant margin, lowers blood pressure and blood sugar, and cuts the risk of heart attacks and strokes in people who already have cardiovascular disease. These results span thousands of participants, multiple trial designs, and follow-up periods ranging from 68 weeks to more than three years.
But the data are strongest for adults in their 60s and early 70s who are relatively functional and free of advanced frailty. For those in their late 70s and beyond, or for people living with dementia, severe mobility limitations, or residence in long-term care, the trials offer less direct guidance. Very frail adults were largely absent from these study populations, and generalizing results to them requires caution.
For an older adult considering semaglutide, the practical conversation with a physician should cover several specifics: current muscle mass and fall risk, the full medication list and potential interactions, realistic expectations about gastrointestinal side effects during the first weeks of treatment, a plan for resistance exercise and adequate protein intake, and a clear understanding of cost and insurance coverage. The question is not simply whether semaglutide works in older adults. The trials confirm that it does. The question is whether it is the right fit for a particular person, with their particular health profile, at this particular point in their life.
As dedicated trials in the oldest age groups and studies measuring muscle preservation alongside cardiovascular outcomes move forward, the picture will sharpen. For now, semaglutide stands as the most rigorously tested pharmacological option for obesity in adults over 65, backed by evidence that would have been unimaginable a decade ago, and accompanied by open questions that honest medicine demands we keep asking.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
